David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease bulk at presentation (Abstract 579).

Lymphoma

Julie Vose, MD, MBA, and David Straus, MD

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and David Straus, MD, of Memorial Sloan Kettering Cancer Center, discuss the initial results of the U.S. Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for nonbulky stage I and II Hodgkin lymphoma (Abstract 578).

Lymphoma

Ronald Go, MD

Ronald Go, MD, on Survival in NHL and Treatment Facility Volume

Ronald Go, MD, of the Mayo Clinic, discusses a study that used the National Cancer Data Base to determine the extent to which the number of non-Hodgkin lymphoma patients treated annually in a facility affects overall survival (Abstract 266).

Leukemia

Andrew D. Zelenetz, MD, PhD

Andrew D. Zelenetz, MD, PhD, on CLL: Idelalisib Plus Bendamustine and Rituximab

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses a late-breaking abstract on the superiority of this three-drug combination compared to bendamustine and rituximab alone in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA5).

Lymphoma

John Leonard, MD

John Leonard, MD, on DLBCL: Results From the Pyramid Trial

John Leonard, MD, of Weill Cornell Medical College, discusses this phase II study of R-CHOP with or without bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma (Abstract 811).

Apr

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Ronald Go, MD, on Survival in NHL and Treatment Facility Volume

Andrew D. Zelenetz, MD, PhD, on CLL: Idelalisib Plus Bendamustine and Rituximab

John Leonard, MD, on DLBCL: Results From the Pyramid Trial

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

Pretreatment MRI Prognostic Information After Radical Prostatectomy

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality